Arbutus Biopharma Corp (ABUS) shareholders
ABUSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 12/3082% below fair value
$4.03+0.15 (+3.87%)
Close on Nov 12, 2026Market cap $797.33MP/E 3.6Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
71.1%
141M of 198M shares
Institutional holders
177
34 new, 22 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Roivant Sciences Ltd. | 29,880,079 | 19.50% | 13D (active) amendment | Oct 1, 2026 |
| Morgan Stanley Joint filing with Morgan Stanley Investment Management Inc. (11.30%) | 18,682,708 | 12.20% | 13G (passive) amendment | Sep 30, 2026 |
| Two Seas Capital GP LLC Joint filing with Two Seas Capital LP (9.40%), Sina Toussi (9.40%) | 18,557,543 | 9.40% | 13G (passive) amendment | Mar 31, 2026 |
| David Salanic Joint filing with Whitefort Capital Master Fund, LP (8.00%), Whitefort Capital GP, LLC (8.00%) and 3 more | 15,794,261 | 8.00% | 13G (passive) | Sep 4, 2026 |
| Whitefort Capital Master Fund, LP Joint filing with Whitefort Capital GP, LLC (8.00%), Whitefort Capital Management, LP (8.00%) and 3 more | 15,794,261 | 8.00% | 13D (active) amendment | Apr 24, 2026 |
| BlackRock, Inc. | 14,331,732 | 7.20% | 13G (passive) amendment | Sep 30, 2026 |
| Two Seas Capital LP Joint filing with Two Seas Capital GP LLC (5.40%), Sina Toussi (5.40%) | 10,443,317 | 5.40% | 13G (passive) | Jun 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ABUS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Two Seas Capital LP | 19,095,583 | 9.65% | $91.66M | +538,040 | 1.82% |
| Morgan Stanley | 17,698,305 | 8.95% | $84.95M | −8,193,175 | 0.00% |
| Whitefort Capital Management, LP | 15,794,261 | 7.98% | $75.81M | +863,376 | 18.69% |
| BlackRock, Inc. | 13,766,071 | 6.96% | $66.08M | +799,125 | 0.00% |
| State Street Corp | 7,869,179 | 3.98% | $37.77M | +1,526,669 | 0.00% |
| Rubric Capital Management LP | 7,532,937 | 3.81% | $36.16M | +906,548 | 0.33% |
| Vanguard Capital Management LLC | 7,010,679 | 3.54% | $33.65M | +321,768 | 0.00% |
| Barclays PLC | 4,207,914 | 2.13% | $20.20M | −108,181 | 0.00% |
| Geode Capital Management, LLC | 4,117,691 | 2.08% | $19.77M | +345,885 | 0.00% |
| Goldman Sachs Group Inc | 3,506,802 | 1.77% | $16.83M | +2,406,368 | 0.00% |
| Bank Of America Corp /De/ | 2,646,197 | 1.34% | $12.70M | +962,569 | 0.00% |
| BlackBarn Capital Partners LP | 2,500,000 | 1.26% | $12.00M | – | 1.01% |
| Legal & General Group Plc | 2,466,127 | 1.25% | $11.84M | +64,738 | 0.00% |
| Woodline Partners LP | 2,281,856 | 1.15% | $10.95M | +271,684 | 0.03% |
| Jefferies Financial Group Inc. | 1,711,672 | 0.87% | $8.22M | −182,395 | 0.05% |
| Nomura Holdings Inc | 1,637,081 | 0.83% | $7.86M | New | 0.01% |
| Vanguard Portfolio Management LLC | 1,541,458 | 0.78% | $7.40M | +149,434 | 0.00% |
| Charles Schwab Investment Management Inc | 1,431,218 | 0.72% | $6.87M | +30,061 | 0.00% |
| Northern Trust Corp | 1,419,024 | 0.72% | $6.81M | +141,165 | 0.00% |
| Osaic Holdings, Inc. | 1,347,866 | 0.68% | $6.47M | −261 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 177 | 141M | 71.1% | 34 / 63 | 41 / 22 | 18M | 16M |
| Q1 2026 | 167 | 139M | 70.3% | 29 / 48 | 48 / 31 | 36M | 9M |
| Q4 2025 | 172 | 122M | 61.7% | 22 / 55 | 45 / 15 | 13M | 9M |
| Q3 2025 | 166 | 118M | 59.8% | 21 / 51 | 54 / 16 | 7M | 7M |
| Q2 2025 | 162 | 118M | 59.8% | 14 / 64 | 45 / 18 | 10M | 3M |
| Q1 2025 | 167 | 112M | 56.5% | 26 / 46 | 52 / 9 | 11M | 3M |
| Q4 2024 | 153 | 104M | 52.6% | 22 / 56 | 41 / 13 | 8M | 5M |
| Q3 2024 | 144 | 101M | 51.1% | 29 / 46 | 32 / 12 | 21M | 5M |
| Q2 2024 | 131 | 97M | 48.9% | 23 / 48 | 31 / 10 | 10M | 15M |
| Q1 2024 | 119 | 101M | 51.1% | 20 / 32 | 35 / 13 | 23M | 8M |
| Q4 2023 | 112 | 86M | 43.5% | 21 / 35 | 28 / 7 | 17M | 6M |
| Q3 2023 | 99 | 75M | 37.9% | 5 / 36 | 23 / 16 | 14M | 5M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
133 funds held ABUS in Q2 2026, 65% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ABUS | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 5,034,547 | 2.54% | $24.17M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 4,110,249 | 2.08% | $19.73M | 0.02% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 3,675,728 | 1.86% | $17.64M | 0.16% | Jun 30, 2026 |
| Morgan Stanley Insight Fund | 2,728,775 | 1.38% | $13.10M | 1.06% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,795,131 | 0.91% | $8.62M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,759,046 | 0.89% | $7.63M | 0.02% | Jul 31, 2026 |
| Inception Portfolio | 1,626,723 | 0.82% | $7.81M | 2.77% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 1,477,677 | 0.75% | $7.09M | 0.05% | Jun 30, 2026 |
| EQ/Morgan Stanley Small Cap Growth Portfolio | 1,299,763 | 0.66% | $6.24M | 1.31% | Jun 30, 2026 |
| iShares Biotechnology ETF | 1,107,700 | 0.56% | $5.32M | 0.06% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 794,940 | 0.40% | $3.62M | 0.01% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 778,182 | 0.39% | $3.55M | 0.02% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 734,401 | 0.37% | $3.35M | 0.01% | May 31, 2026 |
| iShares Micro-Cap ETF | 539,841 | 0.27% | $2.59M | 0.17% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P Kensho New Economies Composite ETF | 537,087 | 0.27% | $2.58M | 0.09% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Lindsay Androski | President and CEO, Director | 47,682 | 0.02% | Oct 7, 2026 |
| Michael J. McElhaugh | Interim President & CEO, Director | 1,658,003 | 0.84% | Feb 19, 2025 |
| Tuan Nguyen | Chief Financial Officer | 111,882 | 0.06% | Oct 7, 2026 |
| J. Christopher Naftzger | General Counsel and CCO | 140,544 | 0.07% | Feb 19, 2025 |
| Karen Sims | Chief Medical Officer | 155,494 | 0.08% | Feb 19, 2025 |
| David C. Hastings | Chief Financial Officer | 249,824 | 0.13% | Feb 19, 2025 |
| Roger Sawhney | Director | 13,683 | 0.01% | Oct 7, 2026 |
| Robert A. Beardsley | Director | 14,328 | 0.01% | Oct 7, 2026 |
| Sciences Ltd. Roivant | Director, 10% owner | 29,880,079 | 15.10% | Oct 5, 2026 |
| Anuj Hasija | Director | – | – | Mar 20, 2025 |
| Matthew Gline | Director, 10% owner | 38,847,462 | 19.64% | Mar 6, 2025 |
| Joseph E. Bishop | Director | – | – | Mar 6, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Robert A. Beardsley Director | Oct 1, 2026 | Returned to company | −17,948 | $5.00 | $89.74K | 14,328 |
| Tuan Nguyen Chief Financial Officer | Oct 1, 2026 | Returned to company | −48,081 | $5.00 | $240.41K | 111,882 |
| Roger Sawhney Director | Oct 1, 2026 | Returned to company | −17,142 | $5.00 | $85.71K | 13,683 |
| Lindsay Androski President and CEO, Director | Oct 1, 2026 | Returned to company | −24,655 | $5.00 | $123.28K | 47,682 |
| Sciences Ltd. Roivant Director, 10% owner | Oct 1, 2026 | Returned to company | −8,967,383 | $5.00 | $44.84M | 29,880,079 |
| Roger Sawhney Director | Sep 18, 2026 | Option exercise | +52,533 | $3.34 | $175.46K | 52,533 |
| Roger Sawhney Director | Sep 18, 2026 | Option exercise | +78,800 | $4.24 | $334.11K | 131,333 |
| Roger Sawhney Director | Sep 18, 2026 | Tax withholding | −100,508 | $5.07 | $509.58K | 30,825 |
| Tuan Nguyen Chief Financial Officer | Sep 18, 2026 | Option exercise | +27,475 | $4.39 | $120.62K | 366,600 |
| Tuan Nguyen Chief Financial Officer | Sep 18, 2026 | Tax withholding | −206,637 | $5.07 | $1.05M | 159,963 |
| Tuan Nguyen Chief Financial Officer | Sep 18, 2026 | Option exercise | +265,625 | $3.49 | $927.03K | 339,125 |
| Robert A. Beardsley Director | Sep 18, 2026 | Option exercise | +78,800 | $4.24 | $334.11K | 131,333 |
| Robert A. Beardsley Director | Sep 18, 2026 | Option exercise | +52,533 | $3.20 | $168.11K | 52,533 |
| Robert A. Beardsley Director | Sep 18, 2026 | Tax withholding | −99,057 | $5.07 | $502.22K | 32,276 |
| Lindsay Androski President and CEO, Director | Sep 18, 2026 | Option exercise | +10,456 | $4.39 | $45.90K | 154,864 |
| Lindsay Androski President and CEO, Director | Sep 18, 2026 | Tax withholding | −82,527 | $5.07 | $418.41K | 72,337 |
| Lindsay Androski President and CEO, Director | Sep 18, 2026 | Option exercise | +116,408 | $3.20 | $372.51K | 144,408 |
| Lindsay Androski President and CEO, Director | Feb 2, 2026 | Award | +28,000 | – | – | 28,000 |
| Tuan Nguyen Chief Financial Officer | Feb 2, 2026 | Award | +73,500 | – | – | 73,500 |
| David C. Hastings Chief Financial Officer | Feb 14, 2025 | Award | +90,100 | – | – | 249,824 |
| Karen Sims Chief Medical Officer | Feb 14, 2025 | Award | +49,300 | – | – | 155,494 |
| J. Christopher Naftzger General Counsel and CCO | Feb 14, 2025 | Award | +54,300 | – | – | 140,544 |
| Michael J. McElhaugh Interim President & CEO, Director | Feb 14, 2025 | Award | +177,000 | – | – | 1,658,003 |
| David C. Hastings Chief Financial Officer | Feb 4, 2025 | Sale(10b5-1 plan) | −22,183 | $3.28 | $72.76K | 159,724 |
| Michael J. McElhaugh Interim President & CEO, Director | Feb 4, 2025 | Sale(10b5-1 plan) | −23,790 | $3.28 | $78.03K | 1,481,003 |
| Karen Sims Chief Medical Officer | Feb 4, 2025 | Sale(10b5-1 plan) | −19,348 | $3.28 | $63.46K | 106,194 |
| J. Christopher Naftzger General Counsel and CCO | Feb 4, 2025 | Sale(10b5-1 plan) | −11,333 | $3.28 | $37.17K | 86,244 |
| Keith S. Manchester Director | Aug 14, 2024 | Option exercise | +54,915 | $0.56 | $30.75K | 54,915 |
| Keith S. Manchester Director | Aug 14, 2024 | Sale | −8,846 | $3.69 | $32.64K | 46,069 |
| Michael J. Sofia Chief Scientific Officer | Feb 2, 2024 | Sale(10b5-1 plan) | −9,982 | $2.31 | $23.06K | 1,485,121 |
| David C. Hastings Chief Financial Officer | Feb 2, 2024 | Sale(10b5-1 plan) | −9,593 | $2.31 | $22.16K | 181,907 |
| Michael J. McElhaugh Interim President & CEO, Director | Feb 2, 2024 | Sale(10b5-1 plan) | −10,164 | $2.31 | $23.48K | 1,504,793 |
| Karen Sims Chief Medical Officer | Feb 2, 2024 | Sale(10b5-1 plan) | −4,358 | $2.31 | $10.07K | 125,542 |
| J. Christopher Naftzger General Counsel and CCO | Feb 1, 2024 | Award | +95,100 | – | – | 95,100 |
| Michael J. Sofia Chief Scientific Officer | Feb 1, 2024 | Award | +109,500 | – | – | 1,495,103 |
| David C. Hastings Chief Financial Officer | Feb 1, 2024 | Award | +112,500 | – | – | 191,500 |
| Michael J. McElhaugh Interim President & CEO, Director | Feb 1, 2024 | Award | +123,800 | – | – | 1,514,957 |
| Karen Sims Chief Medical Officer | Feb 1, 2024 | Award | +101,000 | – | – | 129,900 |
| Michael J. Sofia Chief Scientific Officer | Feb 1, 2023 | Award | +82,200 | – | – | 1,385,603 |
| Elizabeth Howard EVP, GC, Compliance | Feb 1, 2023 | Award | +69,700 | – | – | 86,024 |
| Michael J. McElhaugh Chief Business Officer | Feb 1, 2023 | Award | +83,700 | – | – | 1,391,157 |
| William H. Collier President and CEO, Director | Feb 1, 2023 | Award | +216,500 | – | – | 216,500 |
| David C. Hastings Chief Financial Officer | Feb 1, 2023 | Award | +79,000 | – | – | 79,000 |
| Michael J. Sofia Chief Scientific Officer | Dec 1, 2021 | Sale(10b5-1 plan) | −200,000 | $5.09 | $1.02M | 1,303,403 |
| Sciences Ltd. Roivant 10% owner | Oct 18, 2021 | Conversion | +22,833,922 | – | – | 38,847,462 |
| Michael J. McElhaugh Chief Business Officer | Feb 9, 2021 | Sale(10b5-1 plan) | −20,000 | $5.00 | $100.00K | 1,307,457 |
| Michael J. McElhaugh Chief Business Officer | Dec 14, 2020 | Sale(10b5-1 plan) | −30,000 | $5.00 | $150.00K | 1,337,457 |
| Michael J. McElhaugh Chief Business Officer | Dec 14, 2020 | Sale(10b5-1 plan) | −10,000 | $5.00 | $50.00K | 1,327,457 |
| Michael J. McElhaugh Chief Business Officer | Jul 23, 2020 | Sale(10b5-1 plan) | −20,000 | $5.01 | $100.20K | 1,367,457 |
| Mark J. Murray Director | Nov 28, 2018 | Option exercise | +25,000 | $1.35 | $33.75K | 341,396 |
| Michael J. Sofia Chief Scientific Officer | Aug 13, 2018 | Sale | −4,250 | $9.51 | $40.42K | 167,162 |
| Michael J. Sofia Chief Scientific Officer | Aug 13, 2018 | Sale | −4,250 | $9.51 | $40.42K | 1,499,153 |
| Michael J. Sofia Chief Scientific Officer | Jul 11, 2018 | Sale(10b5-1 plan) | −10,000 | $10.00 | $100.00K | 1,503,403 |
| Michael J. Sofia Chief Scientific Officer | Jul 9, 2018 | Sale(10b5-1 plan) | −10,000 | $8.91 | $89.10K | 1,513,403 |
| Michael J. Sofia Chief Scientific Officer | Jul 6, 2018 | Sale(10b5-1 plan) | −10,000 | $8.45 | $84.50K | 1,523,403 |
| Michael J. Sofia Chief Scientific Officer | Jul 5, 2018 | Sale(10b5-1 plan) | −10,000 | $8.40 | $84.00K | 1,533,403 |
| Michael J. Sofia Chief Scientific Officer | Jul 3, 2018 | Sale(10b5-1 plan) | −10,000 | $8.00 | $80.00K | 1,543,403 |
| Mark J. Murray President & CEO, Director | Apr 17, 2018 | Option exercise | +27,007 | $0.35 | $9.45K | 316,396 |
| Michael J. Sofia Chief Scientific Officer | Oct 3, 2017 | Sale(10b5-1 plan) | −10,000 | $8.00 | $80.00K | 1,553,403 |
| Michael J. Sofia Chief Scientific Officer | Aug 15, 2017 | Sale | −10,000 | $3.75 | $37.50K | 191,412 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
15.69%
20M shares short
Days to cover
9.1
At 2M shares a day
Change since last report
-19.0%
From 25M shares
Short volume, 20 days
54.3%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Arbutus Biopharma's stock actually held short. Settlement fails (shares not delivered on time) peaked at 2,641,844 shares on Oct 2, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Michael J. McElhaugh Director | Apr 21, 2025 | 246,886 | $804.85K | Apr 21, 2025 | Stock Award |
| Michael J. McElhaugh Director | Apr 15, 2025 | 53,114 | $170.10K | Apr 15, 2025 | Stock Award |
| Michael J. Sofia Officer | Mar 31, 2025 | 250,000 | $875.00K | Mar 31, 2025 | Merger Acquisition |
| Michael J. Sofia Officer | Mar 24, 2025 | 250,000 | $820.00K | Mar 24, 2025 | Merger Acquisition |
| Michael J. Sofia Officer | Mar 19, 2025 | 150,000 | $480.00K | Mar 19, 2025 | Merger Acquisition |
| Michael J. Sofia Officer | Mar 13, 2025 | 100,000 | $338.00K | Mar 13, 2025 | Merger Acquisition |
| Michael J. Sofia Member of immediate family of any of the foregoing | Mar 7, 2025 | 167,162 | $549.96K | Mar 7, 2025 | Gift |
| David C. Hastings Officer | Feb 4, 2025 | 22,183 | $72.83K | Feb 4, 2025 | Restricted Stock Unit Vesting |
| J. Christopher Naftzger Officer | Feb 4, 2025 | 11,333 | $37.21K | Feb 4, 2025 | Restricted Stock Unit Vesting |
| Karen Sims Officer | Feb 4, 2025 | 19,348 | $63.52K | Feb 4, 2025 | Restricted Stock Unit Vesting |
| Michael J. McElhaugh Director and Officer | Feb 4, 2025 | 23,790 | $78.10K | Feb 4, 2025 | Restricted Stock Unit Vesting |
See a number that looks wrong?